Literature DB >> 30784192

Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients.

Ammar Sukari1, Misako Nagasaka1,2, Maria Diab1, Khaled Al Sibai3, Bassel Atassi4, Jailan A Elayoubi5, Seongho Kim1, Ömer Küçük6.   

Abstract

Entities:  

Year:  2019        PMID： 30784192      PMCID： PMC6844146          DOI： 10.1111/coa.13316

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN： 1749-4478            Impact factor:   2.597


× No keyword cloud information.
  9 in total

1.  Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.

Authors:  Begoña Jiménez; José M Trigo; Bella I Pajares; Maria I Sáez; Cristina Quero; Victor Navarro; Casilda Llácer; Laura Medina; Antonio Rueda; Emilio Alba
Journal:  Oral Oncol       Date:  2012-09-28       Impact factor: 5.337

2.  Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors.

Authors:  Ammar Sukari; Misako Nagasaka; Nadine Abdallah
Journal:  Oral Oncol       Date:  2018-03-28       Impact factor: 5.337

3.  Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Authors:  R Hitt; A Irigoyen; H Cortes-Funes; J J Grau; J A García-Sáenz; J J Cruz-Hernandez
Journal:  Ann Oncol       Date:  2011-08-23       Impact factor: 32.976

4.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

Authors:  A A Forastiere; B Metch; D E Schuller; J F Ensley; L F Hutchins; P Triozzi; J A Kish; S McClure; E VonFeldt; S K Williamson
Journal:  J Clin Oncol       Date:  1992-08       Impact factor: 44.544

5.  Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

Authors:  Joshua Bauml; Tanguy Y Seiwert; David G Pfister; Francis Worden; Stephen V Liu; Jill Gilbert; Nabil F Saba; Jared Weiss; Lori Wirth; Ammar Sukari; Hyunseok Kang; Michael K Gibson; Erminia Massarelli; Steven Powell; Amy Meister; Xinxin Shu; Jonathan D Cheng; Robert Haddad
Journal:  J Clin Oncol       Date:  2017-03-22       Impact factor: 44.544

6.  Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Authors:  Jan B Vermorken; Ricard Mesia; Fernando Rivera; Eva Remenar; Andrzej Kawecki; Sylvie Rottey; Jozsef Erfan; Dmytro Zabolotnyy; Heinz-Roland Kienzer; Didier Cupissol; Frederic Peyrade; Marco Benasso; Ihor Vynnychenko; Dominique De Raucourt; Carsten Bokemeyer; Armin Schueler; Nadia Amellal; Ricardo Hitt
Journal:  N Engl J Med       Date:  2008-09-11       Impact factor: 91.245

7.  Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.

Authors:  Jan B Vermorken; Roy S Herbst; Xavier Leon; Nadia Amellal; Jose Baselga
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

8.  Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

Authors:  Jan B Vermorken; José Trigo; Ricardo Hitt; Piotr Koralewski; Eduardo Diaz-Rubio; Frédéric Rolland; Rainald Knecht; Nadia Amellal; Armin Schueler; José Baselga
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

9.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245
  9 in total
  1 in total

Review 1.  Shooting at Moving and Hidden Targets-Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas.

Authors:  Joanna Kałafut; Arkadiusz Czerwonka; Alinda Anameriç; Alicja Przybyszewska-Podstawka; Julia O Misiorek; Adolfo Rivero-Müller; Matthias Nees
Journal:  Cancers (Basel)       Date:  2021-12-10       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.